Study highlights processes that act as barriers to use evidence-based pulmonary embolism testing

Common barriers exist to the use of risk stratification tools in the evaluation of pulmonary embolism in the emergency department and provide insight into where to focus efforts for future implementation endeavors.

That is the conclusion of a study to be published in the June 2020 issue of Academic Emergency Medicine (AEM), a journal of the Society for Academic Emergency Medicine (SAEM).

The lead author of the study is Lauren M. Westafer DO, MPH, MS, assistant professor, Department of Emergency Medicine, University of Massachusetts Medical School-Baystate. The findings of the study are discussed in a recent AEM podcast, Teacher, Teacher -- Tell Me How to Do It (Diagnose a PE).

According to the study findings, provider-level factors such as risk avoidance and lack of knowledge of the tools dominated as barriers, while inner-setting factors were identified as facilitators.

The authors recommend that future efforts to improve evidence-based diagnosis of pulmonary embolism should focus on implementation strategies targeting these domains.

This important study highlights several common thought processes which act as barriers for emergency physician use of evidence-based pulmonary embolism testing. The authors identified opportunities to promote adherence to evidence-based testing, including leveraging culture and peer pressure."

Dr. Kerstin de Wit, Assistant Professor, Department of Medicine, McMaster University

Wit is also an mergency and thrombosis physician and Hamilton Health Sciences.

Source:
Journal reference:

Westafer DO, L. M., et al. (2020) Provider Perspectives on the Use of Evidence‐based Risk Stratification Tools in the Evaluation of Pulmonary Embolism: A Qualitative Study. Academic Emergency Medicine. doi.org/10.1111/acem.13908.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Convalescent plasma in COVID-19 can be effective, especially early in disease